Seizure Possibly Associated with Fluvoxamine

Kim, Kye Y.; Craig, Janet M; Hawley, Joanne M.

doi:10.1345/1542-6270(2000)034<1276:spawf>2.0.co;2

Cited by 3 publications

(2 citation statements)

References 0 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…One of the main concerns with anti-depressant use, including SSRIs, is the increased risk of seizures in patients with a previous history of seizures. Additionally there have been case reports of seizures occurring in patients without a previous history of seizures following therapeutic use of fluvoxamine [4,5]. However there has been no data to support the hypothesis of a significant increased risk of seizures with therapeutic doses of fluvoxamine [3,13].…”

Section: Discussionmentioning

confidence: 99%

“…They have improved safety, both in therapeutic use and in overdose, compared to older conventional antidepressant drugs such as the tricyclic anti-depressants and the mono-amine oxidase inhibitors (MAOI) [2]. However, there have been case reports of seizures following therapeutic use of fluvoxamine in patients with and without a history of preexisting seizures [3,4,5]. There have been two previous case reports of repeated multiple self-limiting seizures following overdoses with fluvoxamine, although in both cases there was incomplete toxicological screening undertaken to confirm isolated fluvoxamine ingestion [6,7].…”

Section: Introductionmentioning

confidence: 99%

See 1 more Smart Citation

Status epilepticus following intentional overdose of fluvoxamine: A case report with serum fluvoxamine concentration

Wood

Rajalingam

Greene

et al. 2007

Clinical Toxicology

View full text Add to dashboard Cite

Introduction. Fluvoxamine is a selective serotonin reuptake inhibitor (SSRI) that is used in the management of depression and obsessive compulsive disorders. We report a patient with status epilepticus requiring quadruple anti-convulsant treatment following a fluvoxamine overdose. Case Report. A 25-year-old female presented with drowsiness at 12 hours following deliberate ingestion of 9.6 grams of fluvoxamine. Sixteen hours after ingestion, she developed status epilepticus that required treatment with benzodiazepines (lorazepam and midazolam), thiopentone, phenytoin and phenobarbitone. Her serum fluvoxamine concentration on presentation was 1970 μg/L (therapeutic 160-220 μg/L) and routine toxicological screening was negative for other drugs. She was discharged home after 72 hours with no further episodes of seizures. Discussion. Most patients with fluvoxamine poisoning are either asymptomatic or may develop mild signs of serotonergic toxicity. Although serotonin syndrome and isolated seizures are reported in fluvoxamine poisoning, we report the first patient with confirmed isolated fluvoxamine toxicity who developed status epilepticus.

show abstract

Section: Discussionmentioning

confidence: 99%

Section: Introductionmentioning

confidence: 99%

Status epilepticus following intentional overdose of fluvoxamine: A case report with serum fluvoxamine concentration

Wood

Rajalingam

Greene

et al. 2007

Clinical Toxicology

View full text Add to dashboard Cite

show abstract

Childhood epilepsy in relation to mental handicap and behavioural disorders

Besag¹

2002

Child Psychology Psychiatry

View full text Add to dashboard Cite

Epidemiological studies indicate that there is a high rate of mental retardation and behavioural problems in children with epilepsy. In some cases both the epilepsy and the mental retardation will have a common cause, such as a metabolic disorder or brain trauma. However, in other children, the epilepsy itself may cause either temporary or permanent learning problems. When permanent learning disability can be prevented it is important to treat the epilepsy early and effectively. Children with specific learning difficulties and memory problems can benefit greatly from appropriate management. There are many causes of behavioural disturbance in children with epilepsy. These causes include the epilepsy itself, treatment of the epilepsy, reactions to the epilepsy, associated brain damage/dysfunction and causes that are equally applicable to children who do not have epilepsy. Identifying the cause or causes in each child allows rational management to be provided. Antiepileptic treatment with medication or surgery can either improve the situation or make matters worse. The treatment should be tailored to the needs of the individual child. If surgery is required, there is a strong argument for performing this early in life, both to allow the greatest opportunity for brain plasticity and also to allow the child full benefit from the important developmental and educational years, without the problems that can be associated with the epilepsy. Skilled management of children with epilepsy who have mental retardation and/or behavioural problems can be very rewarding both for the family and for the professionals involved.

show abstract

Therapeutic Potential of Fluoxetine in Neurological Disorders

Mostert

Koch

Heerings

et al. 2008

CNS Neuroscience & Therapeutics

View full text Add to dashboard Cite

The selective serotonin reuptake inhibitor (SSRI) fluoxetine, which is registered for a variety of psychiatric disorders, has been found to stimulate the cAMP-responsive element binding protein (CREB), increase the production of brain-derived neurotrophic factor (BNDF) and the neurotrophic peptide S100beta, enhance glycogenolysis in astrocytes, block voltage-gated calcium and sodium channels, and decrease the conductance of mitochondrial voltage-dependent anion channels (VDACs). These mechanisms of actions suggest that fluoxetine may also have potential for the treatment of a number of neurological disorders. We performed a Pubmed search to review what is known about possible therapeutic effects of fluoxetine in animal models and patients with neurological disorders. Beneficial effects of fluoxetine have been noted in animal models of stroke, multiple sclerosis, and epilepsy. Fluoxetine was reported to improve neurological manifestations in patients with Alzheimer's disease, stroke, Huntington's disease, multiple sclerosis, traumatic brain injury, and epilepsy. Clinical studies so far were small and often poorly designed. Results were inconclusive and contradictory. However, the available preclinical data justify further clinical trials to determine the therapeutic potential of fluoxetine in neurological disorders.

show abstract

Seizure Possibly Associated with Fluvoxamine

Cited by 3 publications

References 0 publications

Status epilepticus following intentional overdose of fluvoxamine: A case report with serum fluvoxamine concentration

Status epilepticus following intentional overdose of fluvoxamine: A case report with serum fluvoxamine concentration

Childhood epilepsy in relation to mental handicap and behavioural disorders

Therapeutic Potential of Fluoxetine in Neurological Disorders

Contact Info

Product

Resources

About